Recovered patient antibody treatments against COVID-19 underway
By MYBRANDBOOK
With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease continues. A growing number of pharmaceutical companies have begun work on recovered patients’ antibody treatments for COVID-19. As monoclonal antibody (mAb) drugs are some of the top sellers in the market today, this approach holds potential, says GlobalData, a leading data and analytics company.
Johanna Swanson, Product Manager at GlobalData, comments: “One approach for these treatments involves identifying the most effective anti-SARS-CoV-2 antibodies from patients who have recovered from the disease. The antibodies are then mass-produced, removing the need for continued plasma from patients, and administered intravenously to current COVID-19 patients to lessen their symptoms.”
One of the companies working on this technique is GigaGen, which is looking to produce whole antibody recombinant immunoglobulin repertoires from recovered patients. The company will use its single-cell technology libraries, which can be directly translated into antibody therapies. These antibodies would be able to block the replication of the virus and be used for passive immunity after intravenous administration. The company is currently seeking recovered patients to donate plasma to begin identification and construction of the antibody libraries. The company is also working with the FDA to speed up development with a goal of reaching clinics in early 2021.
Swanson continued: “This manufacturing process has better batch consistency and lower contamination risk because it is based on a recombinant therapy and not derived from plasma. This increases the consistency as it is not dependant on batches of human plasma, which can vary, and increases its potency as it is the same specific concentrated antibodies produced in each batch.”
Another company working on this treatment is Celltrion Group. The company has completed its identification of the most promising antibody candidates from the blood of recovered patients in Korea in partnership with the Korea Centers for Disease Control and Prevention (KCDC). The company now plans to begin work on cell line development and mass production for these antibodies, with the goal of launching clinical trials in July 2020.
Swanson continues: “This novel treatment has the potential of leveraging the body’s own immune system to create a treatment. With a large number of antibodies examined, there is a high potential to find a promising candidate that has already been selected to be effective and specific. This treatment can be used to lessen the severity of the illness for patients and to provide prophylactic treatments for healthcare workers and immunocompromised individuals.”
BHIM to join e-commerce, competing with PhonePe and Google Pay
The government-supported payment software BHIM is getting ready to join t...
The latest version of X helps prevent deepfakes on social medi
To combat deepfakes and shallowfakes, Elon Musk revealed a new update t...
India and Namibia collaborate on a payment system similar to U
Once operational, the platform will enable digital transactions in Namibia,...
Sebi issues show-cause notices to six Adani group firms
Sebi issued show-cause notices to six Adani Group firms, including Adani ...
FIREBOLTT
MATRIX COMSEC PVT. LTD.
HP INDIA SALES PVT. LTD.
INFOSYS TECHNOLOGIES PVT. LTD.
Technology Icons Of India 2023: Sunil Gupta
Sunil Gupta is the Co-founder, Managing Partner & CEO of Yotta Infrast...
Technology Icons Of India 2023: Bharat Goenka
Bharat Goenka is the Managing Director of Tally Solutions. He is well ...
Technology Icons Of India 2023: Bhavish Aggarwal
Ola CEO Bhavish Aggarwal had formed Ola-India’s largest mobility pla...
NIC bridging the digital divide and supporting government in eGovernance
The National Informatics Centre (NIC) is an Indian government departme...
PGCIL transforming India with its wide power transmission network
Engaged in power transmission, POWERGRID or PGCIL is a stated owned In...
ITI Limited widening its focus area
ITI Limited is a public sector undertaking company, has manufacturing ...
RAH INFOTECH
RAH Infotech is India’s fastest growing technology value added dist...
TEXONIC INSTRUMENTS
Texonic has carved a niche for itself in the Technology Distribution i...
INTEGRA MICRO SYSTEMS PVT. LTD.
Integra is a leading provider of innovative hi-technology products an...